Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Although in vitro models have been a cornerstone of anti-cancer drug development, their direct applicability to clinical cancer research has been uncertain. Using a state-of-the-art Taqman-based quantitative RT-PCR assay, we investigated the multidrug resistance (MDR) transcriptome of six cancer types, in established cancer cell lines (grown in monolayer, 3D scaffold, or in xenograft) and clinical samples, either containing >75% tumor cells or microdissected. The MDR transcriptome was determined a priori based on an extensive curation of the literature published during the last three decades, which led to the enumeration of 380 genes. No correlation was found between clinical samples and established cancer cell lines. As expected, we found up-regulation of genes that would facilitate survival across all cultured cancer cell lines evaluated. More troubling, however, were data showing that all of the cell lines, grown either in vitro or in vivo, bear more resemblance to each other, regardless of the tissue of origin, than to the clinical samples they are supposed to model. Although cultured cells can be used to study many aspects of cancer biology and response of cells to drugs, this study emphasizes the necessity for new in vitro cancer models and the use of primary tumor models in which gene expression can be manipulated and small molecules tested in a setting that more closely mimics the in vivo cancer microenvironment so as to avoid radical changes in gene expression profiles brought on by extended periods of cell culture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Established cell cultures have been the predominant research models of osteosarcoma for decades, but the culture-related alterations that cell lines acquire over tens and sometimes hundreds of passages 220,221 led to the development of systems for propagating osteosarcoma tumours 220,221 by creating libraries of primary tumour cell cultures and patient-derived xenografts (PDXs).”
From Osteosarcoma (2022) · cites this paper as [220]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, it has been shown that established cell lines do not capture disease heterogeneity across patients and hence are lacking in clinical relevance (Gillet et al., 2011; Yee et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Gillet et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our results confirm the low translational relevance of established cancer cell lines for the identification of clinical anti-cancer drug resistance [38].”
From Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“Among those genes, ATP-binding cassette (ABC) transporters, a superfamily of 48 highly homologous members classified in seven subfamilies, have an important role in the pleiotropic mechanisms mediating MDR by exporting chemotherapeutic agents from the cell (14, 15).”
BackgroundSelf-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Cited by
Items 101–200 of 476
Shen, L., Saviano, A., Erstad, D. J., Hoshida, Y., Fuchs, B. C., Baumert, T. F., & Tanabe, K. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123817 · Cited by 57
Chen, T., Luo, J., Gu, Y., Huang, J., Luo, Q., & Yang, Y. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13032 · Cited by 47
Bahar, E., Kim, J., Kim, H.-S., & Yoon, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207613 · Cited by 53
“The establishment of cisplatin-resistant (CisR) human cancer cell lines may be a convenient and effective model system to investigate the molecular mechanisms of cancer drug resistance [22].”
BackgroundCriteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Calvisi, D. F., Boulter, L., Vaquero, J., Saborowski, A. L., Fabris, L., Rodrigues, P. M., Coulouarn, C., Castro, R. E., Segatto, O., Raggi, C., et al. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00739-y · Cited by 51
The bone marrow niche in support of breast cancer dormancy
Walker, N. D., Patel, J. S., Munoz, J. L., Hu, M. D., Guiro, K., Sinha, G., & Rameshwar, P. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.033 · Cited by 51
Photoacoustic imaging of cells in a three-dimensional microenvironment
Liu, W., & Li, P. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0594-x · Cited by 51
Transcriptionally active enhancers in human cancer cells
Lidschreiber, K., Jung, L. A., von der Emde, H., Dave, K., Taipale, J., Cramer, P., & Lidschreiber, M. (2021) · Molecular Systems Biology · doi:10.15252/msb.20209873 · Cited by 51
“However, it is important to consider that cancer cell line models have major limitations and inevitably entail genomic differences as pointed out by several studies (Stein et al , 2004; Sandberg & Ernberg, 2005; Ertel et al , 2006; Gillet et al , 2011).”
Patient-derived cell models as preclinical tools for genome-directed targeted therapy
Lee, J. Y., Kim, S. Y., Park, C., Kim, N. K., Jang, J., Park, K., Yi, J., Hong, M., Ahn, T., Rath, O., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4627 · Cited by 50
DNMT1 is associated with cell cycle and DNA replication gene sets in diffuse large B-cell lymphoma
Loo, S. K., Hamid, S. S. A., Musa, M., & Wong, K. K. (2017) · Pathology - Research and Practice · doi:10.1016/j.prp.2017.10.005 · Cited by 50
Patient-derived tumour xenografts as models for breast cancer drug development
Marangoni, E., & Poupon, M. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000133 · Cited by 52
Assessment of Cancer Cell Line Representativeness Using Microarrays for Merkel Cell Carcinoma
Daily, K., Coxon, A. B., Williams, J. S., Lee, C. R., Coit, D. G., BUSAM, K. J., & Brownell, I. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.518 · Cited by 49
“Microarray expression profiles have been used to compare cancer cell lines to native tumors for a number of cancer types (Barretina et al., 2012; Carlson et al., 2007; Wang et al., 2006; Gillet et al., 2011; Khan et al., 2001; Li et al., 2008).”
MethodWinter, S., Fisel, P., Büttner, F., Rausch, S., D’Amico, D., Hennenlotter, J., Kruck, S., Nies, A. T., Stenzl, A., Junker, K., et al. (2016) · Scientific Reports · doi:10.1038/srep29930 · Cited by 49
Müller, R. (2016) · Biochimie · doi:10.1016/j.biochi.2016.10.019 · Cited by 51
Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
Moro, M., Bertolini, G., Caserini, R., Borzi, C., Boeri, M., Fabbri, A., Leone, G., Gasparini, P., Galeone, C., Pelosi, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06912-7 · Cited by 44
Radiosensitization of brain metastasis by targeting c-MET
Yang, H., Lee, H. W., Kim, Y., Lee, Y., Choi, Y.-S., Kim, K. H., Jin, J., Lee, J., Joo, K. M., & Nam, D. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2012.180 · Cited by 43
Models for Understanding Resistance to Chemotherapy in Liver Cancer
Marin, J. J. G., Herraez, E., Lozano, E., Macias, R. I. R., & Briz, O. (2019) · Cancers · doi:10.3390/cancers11111677 · Cited by 43
Leiva, M. C., Garré, E., Gustafsson, A., Svanström, A., Bogestål, Y. R., Håkansson, J., Ståhlberg, A., & Landberg, G. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30191 · Cited by 42
“However, the adaptability to the microenvironment will be dependent on specific cell line characteristics, as well as genetic abnormalities that might limit and potentially change the drug response (Gillet et al., 2011; Neve et al., 2006).”
BackgroundApplications of organoid technology to brain tumors
Wen, J., Liu, F., Cheng, Q., Weygant, N., Liang, X., Fan, F., Li, C., Zhang, L., & Liu, Z. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14272 · Cited by 46
Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice
Chen, A., Neuwirth, I., & Herndler‐Brandstetter, D. (2023) · Cancers · doi:10.3390/cancers15112989 · Cited by 45
Barriers to generating PDX models of HPV‐related head and neck cancer
Facompre, N. D., Sahu, V., Montone, K. T., Harmeyer, K. M., Nakagawa, H., Rustgi, A. K., Weinstein, G. S., Gimotty, P. A., & Basu, D. (2017) · The Laryngoscope · doi:10.1002/lary.26679 · Cited by 42
New tools for old drugs: Functional genetic screens to optimize current chemotherapy
Gerhards, N. M., & Rottenberg, S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.001 · Cited by 47
“Additionally, comparisons of 14 patient-derived and control cell lines revealed that the variation rather reflects the genetic background, culture conditions and cell line history than a disease-relevant phenotype (Soldner and Jaenisch, 2012, Gillet et al., 2011).”
BackgroundCiucci, A., Buttarelli, M., Fagotti, A., Scambia, G., & Gallo, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04395-y · Cited by 51
“Actually, although it appears that at the genomic level driver mutations are retained, literature data suggest that cancer cell lines resemble each other more than their original clinical samples, this limiting their usefulness and impacting the final overview [6, 7].”
BackgroundCurrent Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
Konstantinopoulos, P. A., & Matulonis, U. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00296 · Cited by 46
Genomic characterization of five commonly used endometrial cancer cell lines
Devor, E. J., Bosquet, J. G., Thiel, K. W., & Leslie, K. K. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5139 · Cited by 47
“While these cells have been the source of numerous breakthroughs in our understanding of cancer biology and have served as the front lines of cancer treatment discovery, there have been contamination with other cell lines, misidentification of cultured cells and reversals in reports of contamination with other cell li…”
BackgroundMourragui, S. M. C., Loog, M., Vis, D. J., Moore, K., Manjón, A. G., van de Wiel, M. A., Reinders, M. J. T., & Wessels, L. F. A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106682118 · Cited by 56
Shen, Y., Tong, M., Liang, Q., Guo, Y., Sun, H. Q., Zheng, W., Ao, L., Guo, Z., & She, F. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.91 · Cited by 41
Tosoni, D., Pambianco, S., Soppo, B. E., Zecchini, S., Bertalot, G., Pruneri, G., Viale, G., Fiore, P. P. D., & Pece, S. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606940 · Cited by 41
“…to treatments, represent more efficacious pre-clinical tools than the traditional, scarcely predictive models, such as established cell lines and their xenografts (DeRose et al, 2011; Gillet et al, 2011; Zhang et al, 2013; Wilding & Bodmer, 2014; Clohessy & Pandolfi, 2015; Whittle et al, 2015).”
BackgroundPatient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
Landuzzi, L., Manara, M. C., Lollini, P.-L., & Scotlandi, K. (2021) · Cells · doi:10.3390/cells10020416 · Cited by 39
Lung cancer organoids, a promising model still with long way to go
Ma, H., Zhu, Y.-J., Zhou, R., Yu, Y., Xiao, Z., & Zhang, H.-B. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103610 · Cited by 45
ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy
Morfouace, M., Cheepala, S., Jackson, S., Fukuda, Y., Patel, Y. T., Fatima, S., Kawauchi, D., Shelat, A. A., Stewart, C. F., Sorrentino, B. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0030 · Cited by 40
“However, established tumor cell lines do not always recapitulate ABC transporter expression and function in vivo (37).”
BackgroundBrodin, B. A., Wennerberg, K., Lidbrink, E. K., Brosjö, O., Potdar, S., Wilson, J. N., Ma, L., Moens, L., Hesla, A. C., Porovic, E., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0359-4 · Cited by 40
“Genes associated with multidrug resistance or with the p53 pathway are reactivated upon in vitro cell culturing.(23) We observed an overexpression of genes associated with autophagy and vesicle formation in the PDCs but not in the biopsy of origin, indicating that in vitro culturing of primary cells activates function…”
BackgroundOlsen, C., Fleming, K. E., Prendergast, N., Rubio, R., Emmert‐Streib, F., Bontempi, G., Haibe‐Kains, B., & Quackenbush, J. F. (2014) · Genomics · doi:10.1016/j.ygeno.2014.03.004 · Cited by 38
“Such comparison between patient samples and laboratory models is recognized as imperfect as colorectal cell lines are not precise models for patient's tumors [15,23].”
BackgroundKadić, E., Moniz, R. J., Huo, Y., Chi, A., & Kariv, I. (2017) · BMC Immunology · doi:10.1186/s12865-017-0192-1 · Cited by 40
“or immortalized cell lines does not always translate to clinical efficacy [69, 70], nor does it recapitulate the complex interactions responsible for cellular homeostasis.”
BackgroundIn Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts
Souto, E. P., Dobrolecki, L. E., Villanueva, H. J., Sikora, A. G., & Lewis, M. T. (2022) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-022-09520-y · Cited by 45
“In fact, transcriptomic comparison of clinical samples to established cancer cell lines revealed all cell lines bear more resemblance to each other rather than the clinical samples they are intended to model [161].”
BackgroundVicent, S., Lieshout, R., Saborowski, A. L., Verstegen, M. M. A., Raggi, C., Recalcati, S., Invernizzi, P., van der Laan, L. J. W., Alvaro, D., Calvisi, D. F., et al. (2019) · Liver International · doi:10.1111/liv.14094 · Cited by 41
Podolski-Renić, A., Jadranin, M. B., Stanković, T., Banković, J., Stojković, S., Chiourea, M., Aljančić, I. S., Vajs, V. E., Tešević, V., Ruždijić, S., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2247-1 · Cited by 38
“Although recent data showed that MDR cancer cell lines, generally, grown either in vitro or in vivo, bear more resemblance to each other, regardless of the tissue of origin, than to the clinical samples they are supposed to model [44], their contribution to preclinical testing of different compounds in the search for…”
BackgroundBotchkina, G. I., Zuniga, E. S., Rowehl, R. A., Park, R., Bhalla, R. S., Bialkowska, A. B., Johnson, F., Golub, L. M., Zhang, Y., Ojima, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069884 · Cited by 37
“In addition, it was recently demonstrated that the most commonly used established cancer cell lines have no correlation with original clinical samples, which can lead to critical misevaluation of drug efficacy [14].”
BackgroundSulaiman, A., McGarry, S., Han, X., Liu, S., & Wang, L. (2019) · Cancers · doi:10.3390/cancers11081128 · Cited by 38
Lui, G. Y. L., Shaw, R. C., Schaub, F. X., Stork, I. N., Gurley, K. E., Bridgwater, C., Diaz, R. L., Rosati, R., Swan, H. A., Ince, T. A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102988 · Cited by 39
Wu, C., Hsiao, S.-H., Su, C.-Y., Luo, S.-Y., Li, Y., Huang, Y.-H., Hsieh, C., & Huang, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.003 · Cited by 35
Onion, D., Argent, R. H., Reece-Smith, A. M., Craze, M. L., Pineda, R. G., Clarke, P. A., Ratan, H. L., Parsons, S. L., Lobo, D. N., Duffy, J. P., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0598 · Cited by 41
“Drug resistance gene signatures of cell lines from the NCI-60 tumor panel in 2D or xenograft culture bare no relation to freshly isolated human tumor, beingmore closely matched to each other than the 6 tumor indications they represented (7).”
BackgroundColchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy
Arnst, K. E., Wang, Y., Lei, Z., Hwang, D., Kumar, G., Ma, D., Parke, D. N., Chen, Q., Yang, J., White, S. W., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.114801 · Cited by 36
“Genetic heterogeneity among cancer cell lines of the same cancer type has emphasized the necessity to study multiple cell lines in a panel (Gillet et al., 2011).”
BackgroundButtarelli, M., Ciucci, A., Palluzzi, F., Raspaglio, G., Marchetti, C., Perrone, E., Minucci, A., Giacò, L., Fagotti, A., Scambia, G., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02265-w · Cited by 32
“Our results confirm the low translational relevance of established cancer cell lines for the identification of clinical anti-cancer drug resistance [38].”
ResultLi, Z., Wang, J., Wang, Z., & Xu, Y. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104601 · Cited by 34
Translational paradigms in pharmacology and drug discovery
Mullane, K., Winquist, R. J., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.019 · Cited by 35
Cortés‐Ciriano, I., & Bender, A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500424 · Cited by 32
Wu, C., Hsieh, Y., Hsiao, S.-H., Su, C.-Y., Li, Y., Huang, Y.-H., Huang, C., Hsieh, C., Yu, J., & Wu, Y. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00687 · Cited by 34
Tashiro, T., Okuyama, H., Endo, H., Kawada, K., Ashida, Y., Ohue, M., Sakai, Y., & Inoue, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174151 · Cited by 33
Yumeen, S., Mirza, F. N., Lewis, J. M., King, A. L. O., Kim, S. R., Carlson, K. R., Umlauf, S., Surovtseva, Y. V., Foss, F. M., & Girardi, M. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001756 · Cited by 33
“Indeed, it has been shown that under prolonged culture, many cell lines, regardless of tissue of origin, behave more like each other than like patient samples.(30) Our data add to this literature, showing the differences in response to targeted treatment in CTCL cell lines and patient-derived samples.”
ResultGao, J., Lan, J., Liao, H., Yang, F., Qiu, P., Jin, F., Wang, S., Shen, L., Chao, T., Zhang, C., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11434-9 · Cited by 40
Efficient and simple approach toin vitroculture of primary epithelial cancer cells
Janik, K., Popęda, M., Peciak, J., Rosiak, K., Smolarz, M., Tręda, C., Rieske, P., Stoczyńska-Fidelus, E., & Książkiewicz, M. (2016) · Bioscience Reports · doi:10.1042/bsr20160208 · Cited by 39
Big Data Approaches for Modeling Response and Resistance to Cancer Drugs
Jiang, P., Sellers, W. R., & Liu, X. S. (2018) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-080917-013350 · Cited by 35
“Despite some studies questioning whether cell line data could capture clinical relevance (162, 163), several studies demonstrated that the data from compound screens could derive reliable biomarkers to predict clinical response to therapies (84, 164, 165).”
A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
Fukamachi, H., Kim, S., Koh, J., Lee, H. S., Sasaki, Y., Yamashita, K., Nishikawaji, T., Shimada, S., Akiyama, Y., Byeon, S., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1121-3 · Cited by 35
Newell, M., Goruk, S., Mazurak, V. C., Postovit, L.-M. M., & Field, C. J. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05331-8 · Cited by 34
On-chip modeling of tumor evolution: Advances, challenges and opportunities
Li, C., Holman, J. B., Shi, Z., Qiu, B., & Ding, W. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100724 · Cited by 39
“Immortalized cancer cells have extensively promoted the understanding of tumor biology [67].”
BackgroundRecent advances in breast cancer cell line research
Sharma, M. P., Shukla, S., & Misra, G. (2024) · International Journal of Cancer · doi:10.1002/ijc.34849 · Cited by 38
“53 Of the established cell lines, only some are able to expand in immunodeficient mice.”
BackgroundRowehl, R. A., Burke, S., Bialkowska, A. B., Pettet, D. W., Rowehl, L., Li, E., Antoniou, E., Zhang, Y., Bergamaschi, R. C., Shroyer, K. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099091 · Cited by 33
“A recent study has demonstrated that, in contrast to the established cancer cell lines, CD133 cells in primary colorectal cancer samples showed a unique genomic aberration profile [20], which additionally highlights the point that the use of established cancer cell line is questionable [3,20,78].”
BackgroundResultInfluentialA Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms
Khazali, A. S., Clark, A. M., & Wells, A. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9735-3 · Cited by 32
“In addition, cell line models for ovarian cancer, glioblastoma, colorectal cancer and metastatic melanoma failed to mimic the gene expression pattern of multi-drug receptor of primary cultures [153].”
BackgroundPatient-derived xenograft models in musculoskeletal malignancies
Wan, L., Chao, T., Chen, R., Su, J., & Li, Z. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1487-6 · Cited by 34
“However, it is believed that these long-established tumor cell lines have adapted to the culture environment, which is quite different from the growing conditions of original tumor, through Darwinian selection after serial passages and thus exhibit irreversible alterations in biological properties, including genetic a…”
BackgroundIndividual Variability of Protein Expression in Human Tissues
Kushner, I., Clair, G., Purvine, S. O., Lee, J., Adkins, J., & Payne, S. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00580 · Cited by 36
Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma
Hansson, K., Radke, K., Aaltonen, K. E., Saarela, J., Mañas, A., Sjölund, J., Smith, E. M. K., Pietras, K., Påhlman, S., Wennerberg, K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4434 · Cited by 34
“Both compounds contain a main 1,3,4-thiadiazole Conventional chemotherapies (74) Kinase inhibitors (262) Rapalogs (5) Immunomodulatory agents (14) Differentiating/epigenetic modifiers (61) Hormone therapies (22) Apoptotic modulators (22) Metabolic modifiers (17) Kinesin inhibitors (3) NSAIDs (2) HSP inhibitors (9) Oth…”
BackgroundPrecision oncology using ex vivo technology: a step towards individualised cancer care?
Williams, S. T., Wells, G., Conroy, S., Gagg, H., Allen, R. J., Rominiyi, O., Helleday, T., Hullock, K., Pennington, C. E. W., Rantala, J., et al. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.32 · Cited by 37
“101).”
Cianfriglia, M. (2013) · PubMed · doi:10.4415/ann_13_02_07 · Cited by 32
Dieter, S. M., Giessler, K. M., Kriegsmann, M., Dubash, T. D., Möhrmann, L., Schulz, E. R., Siegl, C., Weber, S., Strakerjahn, H., Oberlack, A., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30561 · Cited by 33
Computational estimation of quality and clinical relevance of cancer cell lines
Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31
“When considering transcriptional components involved in multidrug resistance (MDR), CCLs were observed to exhibit upregulation of genes that would facilitate survival (Gillet et al , 2011).”
BackgroundVaratharajan, S., Abraham, A., Karathedath, S., Ganesan, S., Lakshmi, K. M., Arthur, N. B. J., Srivastava, V. M., George, B., Srivastava, A., Mathews, V., et al. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0150 · Cited by 30
Predicting Tumor Sensitivity to Chemotherapeutic Drugs in Oral Squamous Cell Carcinoma Patients
Robert, B. M., Muralidharan, D., Brindha, G. R., Dhandapani, M., Radhiga, T., Muthusamy, G., Nirmal, R. M., & Prasad, N. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-33998-4 · Cited by 33
Recently identified drug resistance biomarkers in ovarian cancer
Davidson, B. (2016) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1156532 · Cited by 30
“research, they may have limited value as a faithful model of chemoresistance in clinical material [4].”
BackgroundClinical Implementation of Precision Medicine in Gastric Cancer
Jeon, J., & Cheong, J. (2019) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2019.19.e25 · Cited by 31
“Moreover, most established cell lines are susceptible to genetic alterations owing to prolonged in vitro culture [34,35].”
BackgroundCurrent methods in translational cancer research
Lee, M. W., Miljanic, M., Triplett, T., Ramírez, C., Aung, K. L., Eckhardt, S., & Capasso, A. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09931-5 · Cited by 33
Simon, B. R., Wilson, M. J., & Wickliffe, J. K. (2014) · Toxicology Reports · doi:10.1016/j.toxrep.2014.05.010 · Cited by 29
Binder, Z. A., Wilson, K. M., Salmasi, V., Orr, B. A., Eberhart, C. G., Siu, I., Lim, M. K., WEINGART, J. D., Quiñones‐Hinojosa, A., Bettegowda, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150271 · Cited by 31
“In a broader sense, prolonged passaging, immortalization, and culture conditions have been shown to alter non-glioma adherent models until they are no longer ideally suited for preclinical studies [26, 27].”
BackgroundWang, W., Yang, Z., Xiao, X., An, T., Li, B., Ouyang, J., Li, H., Wang, C., Zhang, Y., Zhang, H., et al. (2020) · Journal of Cancer · doi:10.7150/jca.40744 · Cited by 29
“Although the traditional cancer cell lines are valuable in the investigation of fundamental cancer research mechanisms, these models have the significant disadvantage and little resemblance to the intended patient tumor[18,19,20,21].”
de Souza, P. S., Madigan, J. P., Gillet, J., Kapoor, K., Ambudkar, S. V., Maia, R. C., Gottesman, M. M., & Fung, K. L. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.06.005 · Cited by 30
“For expression levels of the 380 MDR-associated genes detected by a custom-made TLDA [24] and a TaqMan Array Human Apoptosis 96-well plate, both from Applied Biosystems, procedures were performed according to the manufacturer's instructions.”
MethodInfluentialKalla, J., Pfneissl, J., Mair, T., Tran, L., & Egger, G. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00960-8 · Cited by 33
“Therefore, research relying solely on cell lines does not successfully translate from bench to bedside [ 5, 6].”
Traditional and Advanced Cell Cultures in Hematopoietic Stem Cell Studies
Ribeiro-Filho, A. C., Levy, D., Ruiz, J. L. M., Mantovani, M. D. C., & Bydlowski, S. P. (2019) · Cells · doi:10.3390/cells8121628 · Cited by 32
“As 3D culture could result in resistance to drugs, it can be a good screening tool for drug evaluation prior to the administration of chemotherapic drugs [74,83].”
BackgroundLiu, X., Li, C., Wan, Z., Chiu, M. C., Huang, J., Yu, Y., Zhu, L., Cai, J., Rong, L., Song, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01247-w · Cited by 32
“In addition, during the procedure to derive cell lines, cells extracted from native tissues undergo an array of biological alterations in order to adapt and grow on the plastic surface of culture plates.(17,40,41) Thus, the ultimate derivation of cell lines represents the survivorship of adapted and altered cells.”
3D bioprinting tumor models mimic the tumor microenvironment for drug screening
Mi, X., Su, Z. Y., Yue, X., Ya, R., Yang, X. F., Qiang, L., Kong, W., Ma, Z., Zhang, C., & Wang, J. (2023) · Biomaterials Science · doi:10.1039/d3bm00159h · Cited by 29
Revisiting the concept of a cytopathic viral infection
Heaton, N. S. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006409 · Cited by 29
Simeone, K., Guay-Lord, R., Lateef, M. A., Péant, B., Kendall‐Dupont, J., Orimoto, A. M., Carmona, E., Provencher, D. M., Saad, F., Gervais, T., et al. (2019) · Lab on a Chip · doi:10.1039/c8lc00982a · Cited by 33
The roles of patient‐derived xenograft models and artificial intelligence toward precision medicine
Babu, J. V., ArulJothi, K. N., Mythili, V. M. R., Singh, S. K., Prasher, P., Gupta, G., Dua, K., Rakshith, H. S., Kaliappan, K., & Anand, K. (2024) · MedComm · doi:10.1002/mco2.745 · Cited by 32
“133,134 As stated earlier, PDX models retain the heterogeneity of patient tumors, allowing for investigating the efficacy of therapies.”
BackgroundEstablishment and evaluation of four different types of patient-derived xenograft models
Ji, X., Chen, S., Guo, Y., Li, W., Qi, X., Yang, H., Xiao, S., Fang, G., Hu, J., Wen, C., et al. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0497-4 · Cited by 27
Fang, B., Kannan, A., Zhao, S., Nguyen, Q., Ejadi, S., Yamamoto, M., Barreto, J. C., Zhao, H., & Gao, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-65637-2 · Cited by 29
Engineered ECM models: Opportunities to advance understanding of tumor heterogeneity
Shimpi, A. A., & Fischbach, C. (2021) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2021.04.001 · Cited by 29
Complex Tumor Spheroids, a Tissue-Mimicking Tumor Model, for Drug Discovery and Precision Medicine
Kaur, G., Evans, D. M., Teicher, B. A., & Coussens, N. P. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211038362 · Cited by 25
The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery
Bae, J., Choi, Y. S., Cho, G., & Jang, S. J. (2022) · Cancers · doi:10.3390/cancers14092144 · Cited by 27
“However, cancer cells cultured using a two-dimensional (2D) monolayer culture method have a major disadvantage because their characteristics may change depending on the culture environment and period [20,21].”
Harnessing preclinical models for the interrogation of ovarian cancer
Qin, T., Fan, J., Lu, F., Zhang, L., Liu, C., Xiong, Q., Zhao, Y., Chen, G., & Sun, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02486-z · Cited by 32
“OC: Ovarian cancer; PDX: Patient-derived xenograft; PDO: Patient-derived organoid; PDE: Patient-derived explant; GEMMs: Genetically engineered mouse models; PARP: Poly ADP-ribose polymerase; PARPi: PARP inhibitor; BRCA : Breast cancer susceptibility gene; FBS: Fetal bovine serum; HGSOC: High-grade serous ovarian carci…”
BackgroundBiliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine
Leiting, J. L., Murphy, S. J., Bergquist, J. R., Hernandez, M. C., Ivanics, T., Abdelrahman, A. M., Yang, L., Lynch, I. T., Smadbeck, J. B., Cleary, S. P., et al. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100068 · Cited by 27
“Cell lines in particular have been found to have more resemblance to cell lines derived from other tumor types than to the original clinical sample they were derived from, and previous work has shown little to no correlation with clinical therapeutic efficacy.(19) These limitations restrict the translational value of…”
ResultMerkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models
Pedersen, E. A., Verhaegen, M. E., Joseph, M., Harms, K. L., & Harms, P. W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1413793 · Cited by 33
Sciarrillo, R., Wojtuszkiewicz, A., Kooi, I. E., Gómez‐Mellado, V. E., Boggi, U., Jansen, G., Kaspers, G. J. L., Cloos, J. J., & Giovannetti, E. (2016) · Journal of Visualized Experiments · doi:10.3791/54714 · Cited by 33
“Therefore, in order to improve the study of drug resistance, more effort should be directed toward the development of novel preclinical models, such as primary cultures and xenografts, that more closely mimic the in vivo cancer microenvironment so as to avoid relevant changes in cellular characteristics caused by exte…”
BackgroundAasebø, E., Forthun, R. B., Berven, F. S., Selheim, F., & Hernandez-Valladares, M. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150826115626 · Cited by 29
“[39] investigated multidrug resistance (MDR) mechanisms in 59 of 60 cancer cell lines defined as the NCI60 panel, and compared their results to a series of primary cancer cells from matched diseases (ovarian serous carcinoma, glioblastoma, colorectal cancer, AML and T-ALL, metastatic melanoma and breast cancer).”
Tong, M., Zheng, W., Li, H., Li, X., Ao, L., Shen, Y., Liang, Q., Li, J., Hong, G., Yan, H., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.51 · Cited by 26
Modeling molecular development of breast cancer in canine mammary tumors
Graim, K. S., Gorenshteyn, D., Robinson, D. G., Carriero, N. J., Cahill, J. A., Chakrabarti, R., Goldschmidt, M. H., Durham, A. C., Funk, J., Storey, J. D., et al. (2020) · Genome Research · doi:10.1101/gr.256388.119 · Cited by 29
“A standard published classification system on canine mammary gland tumors was used to classify and grade all tumors/tissues by board certified Veterinary Pathologists (Goldschmidt and Durham) (Goldschmidt et al. 2011).”
MethodCharbonneau, M., Harper, K., Brochu‐Gaudreau, K., Perreault, A., Roy, L.-O., Lucien, F., Tian, S., Fortin, D., & Dubois, C. M. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad047 · Cited by 29
Osrodek, M., Hartman, M. L., & Czyż, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174203 · Cited by 27
“Therefore, despite the undeniable value of cell line-based research, the model is rather flawed and its direct contribution to clinical cancer research is questionable [34].”
BackgroundBioengineering Models for Breast Cancer Research
Guiro, K., & Arinzeh, T. L. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s29424 · Cited by 28
Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy
Jarrar, A., Lotti, F., DeVecchio, J., Ferrandon, S., Gantt, G., Mace, A. G., Karagkounis, G., Orloff, M., Venere, M., Hitomi, M., et al. (2018) · Stem Cells · doi:10.1002/stem.2929 · Cited by 28
Tissue specificity of in vitro drug sensitivity
Yao, F., Tonekaboni, S. A. M., Safikhani, Z., Smirnov, P., El-Hachem, N., Freeman, M., Manem, V. S., & Haibe‐Kains, B. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocx062 · Cited by 24
Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1
Garcia, E., Hayden, A. L., Birts, C. N., Britton, E., Cowie, A., Pickard, K. M., Mellone, M., Choh, C., Derouet, M. F., Duriez, P. J., et al. (2016) · Scientific Reports · doi:10.1038/srep32417 · Cited by 28
Ao, L., Guo, Y., Song, X., Guan, Q., Zheng, W., Zhang, J., Huang, H., Zou, Y., Guo, Z., & Wang, X. (2017) · Liver International · doi:10.1111/liv.13467 · Cited by 25
Metadata
- Authors
- Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., Padmanabhan, R., Davidson, B., Ganapathi, R., Sood, A. K., Rueda, B. R., Ambudkar, S. V., & Gottesman, M. M.
- Affiliations
- National Cancer Institute (UA)
- National Institutes of Health (US)
- Biophase Systems, Fremont, CA 94539;
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-11-08
- Volume
- 108
- Issue
- 46
- Pages
- 18708-18713
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3219108
- OpenAlex
- W2018044006
- Cited by
- 477
- References
- 46
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 25 · 2023: 43 · 2022: 28 · 2021: 34 · 2020: 41 · 2019: 45 · 2018: 33 · 2017: 46 · 2016: 40 · 2015: 40 · 2014: 20 · 2013: 29 · 2012: 16
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repository of the University of Namur (submittedVersion)
- Funders
- Georgetown University
- Karolinska Institutet
- National Institutes of Health
- Lombardi Comprehensive Cancer Center, Georgetown University
- National Cancer Institute (NCI-60)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- cancer cell lines, multidrug resistance, drug resistance mechanisms, xenografts, 3D cell culture, gene expression profiles, in vitro tumor model, tumor microenvironment
- MeSH terms
- Antineoplastic Agents, Cell Survival, Drug Screening Assays, Antitumor, Female, Humans, Ovarian Neoplasms, Ovary, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Cell Line, Tumor, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.